 |
 |
Hi, there was a mention of research re:retina and dopamine not so long ago. Would someone have the message still available? Please send it to me again. Someone is interested in facilitating discussion about the matter with medical researchers and would like to have it as background. Thank you. Ansa Ojanlatva, PhD, CHES (ret.) Docent, Health and Sexuality Education Authorized Sexuality Educator and Sexual Health Promotor (NACS), Authorized in Sexual Science (NACS) Sanitas 3rd floor Lemminkäisenkatu 1 20014 University of Turku, Finland mobile +358-400-823 816 tel +358-2-333 8515 fax +358-2-333 8439 Please use the mobile phone number for calling. ----- Original Message ----- From: rayilynlee <[log in to unmask]> Date: Thursday, August 20, 2009 9:04 am Subject: Loss of sex drive in PD To: [log in to unmask] > from Viartis > > 19th August 2009 - New research > THE LOSS OF SEX DRIVE IN PARKINSON'S DISEASE > The journal of sexual medicine [2009] 6 (4) : 1024-1031 (Kummer A, > Cardoso > F, Teixeira AL) Complete abstract > > Sexual dysfunction is a frequent but neglected problem in Parkinson's > > Disease, as muscular problems are usually seen as the characteristic > symptoms. However, nearly two thirds (65.6%) of people with > Parkinson's > Disease have been found to suffer a loss of sex drive. Over 42% of > those men > with Parkinson's Disease also complained of erectile dysfunction. > Ageing, > female gender, lower education, and depression were most associated > with > decreased sexual desire. Decreased interest in sex was not associated > with > antidepressants. The neurological features that were most associated > with a > greater loss of sex drive were predominance of motor symptoms on the > left > side of the body, autonomic dysfunction, and severer Parkinson's > Disease. In > order to refer to this article on its own click here. > > 16th August 2009 - New report > A FUTURE REPLACEMENT FOR SINEMET > According to a new report, Depomed are developing a new drug called > DM-1992 > that could outperform Sinemet in the treatment of Parkinson's Disease. > For > their report click here. The details are on page 20. Just like > Sinemet, > DM-1992 is a combination of L-dopa and carbidopa, which prevents the > breakdown of L-dopa. DM-1992 also includes AcuForm, which makes use > of the > properties of certain polymers. These polymers have long been used to > > "fluff" ice cream and are safe to use. For more information go to > Depomed. > Upon entering the stomach an AcuForm coated pill expands and is > retained in > the stomach for up to 8 hours. This helps to deliver a drug like > Sinemet > over a longer period of time. Depomed's formulation was able to extend > the > therapeutic duration of L-dopa to nine hours, compared to Sinemet CR's > seven > hours. The time to reach peak blood levels was extended to four hours > > compared to 2 hours for Sinemet CR. These advantages could enable a > decrease > in the dosage of L-dopa, and the ridding of side effects such as > nausea and > dyskinesia. In order to refer to this article on its own click here. > > Rayilyn Brown > Director AZNPF > Arizona Chapter National Parkinson Foundation > [log in to unmask] > > ---------------------------------------------------------------------- > To sign-off Parkinsn send a message to: mailto:[log in to unmask] > In the body of the message put: signoff parkinsn ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn